Found 3 articles for: "Nemolizumab"
Atopic Dermatitis Flare Following Initiation of Nemolizumab
August 2026 | Volume 25 | Issue 8 | Case Reports | 751 | Copyright © August 2026
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder marked by intense pruritus and episodic flares. While nemolizumab, an interleukin-31 (IL-31) inhibitor,...
Read MoreResolution of Lichen Simplex Chronicus With Nemolizumab: A Case Report
December 2025 | Volume 24 | Issue 12 | Case Reports | 1252 | Copyright © December 2025
Introduction: Lichen simplex chronicus is a debilitating condition characterized by lichenified skin secondary to intractable itch. Lichen simplex chronicus is challenging to tre...
Read MoreSelection of Nemolizumab Clinical Dosage for Atopic Dermatitis
October 2023 | Volume 22 | Issue 10 | Original Article | 1017 | Copyright © October 2023
Nemolizumab is a monoclonal antibody directed against the interleukin-31 receptor A subunit, which is involved in the pathogenesis of pruritus and inflammation in atopic dermatitis (AD). Clinical tria...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.